Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Status:
Recruiting
Trial end date:
2022-06-25
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary
efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in
participants with advanced solid tumors.